Additionally, pharmacologic RhoA/ROCK inhibition reduced the production of anti-dsDNA antibody levels and the responsiveness of B cells to B-cell activating factor receptor (BAFF/ BAFFR) (33, 38),suggesting a role in the differentiation of autantibody producing B lymphocytes in SLE (39). Here, RHOA is linked to systemic lupus erythematosus.